Clinical trial · Observational
Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma
Impact of Acupuncture on Acute Dysphagia in Patients Treated With Radio-chemotherapy for Head and Neck Squamous Cell Carcinoma: a Randomized Phase 2 Study
NCT05143268CI-TRIAL-00062125ACP-HNunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a randomized phase 2 study on the impact of acupuncture on acute dysphagia in patients treated with radio-chemotherapy for head and neck squamous cell carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- A
- description
- In the experimental arm (arm A), a total of 11 sessions of acupuncture will be performed on a weekly basis, spanning from 2 weeks before Radiotherapy start throughout 7 weeks of treatment, to 2 weeks after its completion. Patients randomized to the experimental arm will receive acupuncture in addition to standard of care treatment, chosen by the treating multidisciplinary team in accordance with international guidelines.
- label
- B
- description
- In the standard arm (arm B), patients will be treated with standard of care treatment.
Primary outcomes (1)
- measure
- Primary objective
- timeFrame
- two weeks after the end of treatment
- description
- Swallowing function assessed with MDADI scale (MD Anderson Dysphagia Inventory)
Secondary outcomes (9)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically-confirmed diagnosis of squamous cell carcinoma of the nasopharynx, oropharynx, hypopharynx and larynx or histologically-confirmed diagnosis of undifferentiated carcinoma of the nasopharynx * by judgement of the local investigator, indication for a DNST with curative intent, consisting of one of the 3 following options: * radiotherapy alone * cisplatin-based concomitant chemo-radiotherapy * cetuximab-based concomitant bio-radiotherapy * clinical stage of disease: II, III, IVA, IVB (according to TNM/AJCC 8th edition) for primary tumors of the larynx, hypopharynx and oropharynx (p16/HPV negative), provided that for stage II disease (cT2N0) the local investigator will prescribe an elective irradiation of regional lymph nodes * clinical stage of disease: I, II, III (according to TNM/AJCC 8th edition) for primary tumors of the oropharynx (p16/HPV positive), provided that for stage I disease (cT1N0) the local investigator will prescribe an elective irradiation of regional lymph nodes Exclusion Criteria: * histologically-confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including patients with HNSCC of unknown primary or non-squamous histologies * metastatic disease * gross total excision of both primary and nodal disease before index treatment * surgical manipulation including therapeutic tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease * prior radiotherapy to the head and neck region * induction chemotherapy prior to radiotherapy * prior use of acupuncture for SCCHN or for different indications * prior allergic reaction or history of hypersensitivity to inox austenitic steel (Cr18Ni9) * active or prior documented neurologic or rheumatologic disorder with a potential impact on the swallowing function (i.e: multiple sclerosis, amyotrophic lateral sclerosis, scleroderma) * active process of severe skin infection in the neck contraindicating the execution of acupuncture in the opinion of the investigator * severe baseline dysphagia documented by a MDADI scale (MD Anderson Dysphagia Inventory) composite score below 60 * any condition that, in the opinion of the investigator, would not require to encompass at least ipsilateral neck lymph nodes in the irradiation field * any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
References
Publications (0)
Data not yet available
No reference posted for this study.